Anti-N-methyl-D-aspartate-receptor encephalitis: Diagnosis, optimal management, and challenges

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 517-524

  Mann, Andrea P ^a   Grebenciucova, Elena ^b   Lukas, Rimas V ^b  

^a Department of Psychiatry and Behavioral Neuroscience ^*  (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Anti NMDA receptor; Complications; Encephalitis; Management; Paraneoplastic; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID; AMANTADINE; AUTOANTIBODY; AZATHIOPRINE; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMATE RECEPTOR; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOSUPPRESSIVE AGENT; KETAMINE; LORAZEPAM; METHYLPREDNISOLONE; MOOD STABILIZER; MYCOPHENOLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; QUETIAPINE; RECEPTOR ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE PSYCHOSIS; AGE DISTRIBUTION; AGGRESSION; AGITATION; AKATHISIA; AMNESIA; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ARTIFICIAL VENTILATION; AUTOMUTILATION; AUTONOMIC DYSFUNCTION; BIPOLAR DISORDER; BRADYCARDIA; BRAIN BIOPSY; CANCER SCREENING; CANCER SURGERY; CATATONIA; CEREBROSPINAL FLUID CYTOLOGY; CHOREOATHETOSIS; COMA; CONSCIOUSNESS DISORDER; CONTRAST ENHANCEMENT; DELAYED DIAGNOSIS; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISEASE PREDISPOSITION; DRUG CHOICE; DRUG DOSE INCREASE; DRUG MONITORING; DRUG TREATMENT FAILURE; DYSKINESIA; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; ETHNIC DIFFERENCE; EVENING DOSAGE; FAMILY COUNSELING; FATALITY; FATIGUE; FEVER; GENETIC RISK; HALLUCINATION; HEADACHE; HERPES SIMPLEX ENCEPHALITIS; HIPPOCAMPUS; HUMAN; HYPERACTIVITY; HYPERSALIVATION; HYPERTENSION; HYPERTHERMIA; HYPOTENSION; HYPOVENTILATION; IMMUNOSUPPRESSIVE TREATMENT; IMPULSE CONTROL DISORDER; IMPULSIVENESS; INSOMNIA; LONG TERM POTENTIATION; LOW DRUG DOSE; LYMPHOCYTOSIS; MALIGNANT CATATONIA; MEDICAL EDUCATION; MEDICAL HISTORY; MEDICAL SPECIALIST; MENTAL INSTABILITY; METABOLIC DISORDER; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NAUSEA; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; OVARY TERATOMA; PARANEOPLASTIC SYNDROME; PARANOIA; PATHOPHYSIOLOGY; PATIENT MONITORING; PATIENT SAFETY; PLASMAPHERESIS; PROGNOSIS; PROTEIN FUNCTION; PSYCHOSIS; RARE DISEASE; REHABILITATION CARE; RELAPSE; REMISSION; REVIEW; RHABDOMYOLYSIS; SCHIZOPHRENIA; SEIZURE; SERODIAGNOSIS; SEX DIFFERENCE; SLEEP DISORDER; SPEECH DISORDER; TACHYCARDIA; TEAMWORK; TERATOMA; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VOMITING;

EID: 84903790009     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S61967     Document Type: Review

References (50)

1. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2): 157-165.
2. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74.
3. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Para-neoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58(4):594-604.
4. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36.
5. Mann A, Machado NM, Liu N, Mazin AH, Silver K, Afzal KI. A multidisciplinary approach to the treatment of anti-NMDA-receptor antibody encephalitis: a case and review of the literature. J Neuropsychiatry Clin Neurosci. 2012;24(2):247-254.
6. Cahalan S. Brain on Fire: My Month of Madness. New York: Simon and Schuster; 2012.
7. Granerod J, Ambrose HE, Davies N W, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10(12): 835-844.
8. Vora NM, Holman RC, Mehal JM, Steiner CA, Blanton J, Sejvar J. Burden of encephalitis-associated hospitalizations in the United States, 1998-2010. Neurolog y. 2014;82(5):443-451.
9. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098.
10. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54(7):899-904.
11. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d- aspartate receptor encephalitis. JAMA Neurol. 2013;70(9): 1133-1139.
12. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66(1):11-18.
13. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133(Pt 6):1655-1667.
14. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866-5875.
15. Bliss T V, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361(6407):31-39.
16. Newcomer J W, Farber NB, Olney J W. NMDA receptor function, memory, and brain aging. Dialogues Clin Neurosci. 2000;2(3):219-232.
17. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301-1308.
18. Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull. 2012;38(5):958-966.
19. Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20(2):106-118.
20. Lin CH, Huang YJ, Lane HY, Tsai GE. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease. Curr Pharm Des. Epub January 9, 2014.
21. Niciu MJ, Ionescu DF, Richards EM, Zarate CA Jr. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm. Epub December 8, 2013.
22. Steiner J, Walter M, Glanz W, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specifc relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry. 2013;70(3):271-278.
23. Hammer C, Stepniak B, Schneider A, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry. Epub September 3, 2013.
24. Wandinger K P, Saschenbrecker S, Stoecker W, Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol. 2011;231(1-2):86-91.
25. van de Riet EH, Esseveld MM, Cuypers L, Schieveld JN. Anti-NMDAR encephalitis: a new, severe and challenging enduring entity. Eur Child Adolesc Psychiatry. 2013;22(5):319-323.
26. Chapman MR, Vause HE. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry. 2011;168(3): 245-251.
27. Kruse JL, Jeffrey JK, Davis MC, Dearlove J, Ishak WW, Brooks JO 3 rd. Anti-N-methyl-d-aspartate receptor encephalitis: a targeted review of clinical presentation, diagnosis, and approaches to psychopharmacologic management. Ann Clin Psychiatry. 2014;26(1):E1-E9.
28. Coyle JT, Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol. 2004;59: 491-515.
29. Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007;78:69-108.
30. Maneta E, Garcia G. Psychiatric manifestations of anti-NMDA receptor encephalitis: neurobiological underpinnings and differential diagnostic implications. Psychosomatics. 2014;55(1):37-44.
31. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the fnal common pathway on the road to schizophrenia? Brain Res Bull. 2010;83(3-4):108-121.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington: American Psychiatric Association; 2013.
33. Millichap JJ, Goldstein JL, Laux LC, Nordli DR Jr, Stack C V, Wainwright MS. Ictal asystole and anti-N-methyl-D-aspartate receptor antibody encephalitis. Pediatrics. 2011;127(3):e781-e786.
34. Gable MS, Gavali S, Radner A, et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis. 2009;28(12):1421-1429.
35. Leypoldt F, Titulaer MJ, Aguilar E, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurolog y. 2013;81(18):1637-1639.
36. Hoftberger R, Armangue T, Leypoldt F, Graus F, Dalmau J. Clinical Neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-D-aspartate receptor antibodies are part of the problem. Clin Neuropathol. 2013;32(4):251-254.
37. Finke C, Kopp UA, Scheel M, et al. Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. Epub May 20, 2013.
38. Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11):1094-1100.
39. Camdessanche J P, Streichenberger N, Cavillon G, et al. Brain immunohistopathological study in a patient with anti-NMDAR encephalitis. Eur J Neurol. 2011;18(6):929-931.
40. Varvat J, Lafond P, Page Y, Coudrot M, Reynaud-Salard M, Tardy B. Acute psychiatric syndrome leading young patients to ICU: consider anti-NMDA-receptor antibodies. Anaesth Intensive Care. 2010;38(4): 748-750.
41. Nosadini M, Boniver C, Zuliani L, et al. Longitudinal electroencepha-lographic (EEG) fndings in pediatric anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis: the Padua experience. J Child Neurol. Epub January 5, 2014.
42. Lesher A P, Myers TJ, Tecklenburg F, Streck CJ. Anti-N-methyl-D-aspartate receptor encephalitis associated with an ovarian teratoma in an adolescent female. J Pediatr Surg. 2010;45(7):1550-1553.
43. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607.
44. Titulaer MJ, Soffetti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19-e3.
45. Houtrow AJ, Bhandal M, Pratini NR, Davidson L, Neufeld JA. The rehabilitation of children with anti-N-methyl-D-aspartate-receptor encephalitis: a case series. Am J Phys Med Rehabil. 2012;91(5): 435-441.
46. Borlot F, Santos ML, Bandeira M, et al. Anti-N-methyl D-aspartate receptor encephalitis in childhood. J Pediatr (Rio J). 2012;88(3): 275-278.
47. Iizuka T, Yoshii S, Kan S, et al. Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. J Neurol. 2010;257(10):1686-1691.
48. Braakman HM, Moers-Hornikx VM, Arts BM, Hupperts RM, Nicolai J. Pearls and Oy-sters: electroconvulsive therapy in anti-NMDA receptor encephalitis. Neurolog y. 2010;75(10):e44-e46.
49. Lee A, Glick DB, Dinwiddie SH. Electroconvulsive therapy in a pediatric patient with malignant catatonia and paraneoplastic limbic encephalitis. J ECT. 2006;22(4):267-270.
50. Watkins CJ, Pei Q, Newberry NR. Differential effects of electrocon-vulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b. Brain Res Mol Brain Res. 1998;61(1-2):108-113.